Hemoglobinopathy Market

Hemoglobinopathy Market, by Test Type (Routine Red Blood Cell (RBC) count, Genetic Testing, Hemoglobin by high performance liquid chromatography, Hemoglobin isoelectric focusing (Hb IEF), Hemoglobin electrophoresis (Hb ELP), Hemoglobin solubility test), by Indication (Sickle Cell Disease, Beta Thalassemia, Alpha Thalassemia), by End User (Hospitals, Diagnostic Laboratories, Clinics), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)- Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030

Hemoglobinopathy are a group of disorders that are inherited, in which there is abnormal production or structure of the hemoglobin molecule. Hemoglobinopathy is the medical term for a group of inherited blood disorders and diseases that primarily affect red blood cells. Sickle cell disease (SCD) is one such blood disorder caused by the abnormal hemoglobin that damages and deforms red blood cells. There are two main groups, which are abnormal structural hemoglobin variants caused by mutations in the hemoglobin genes, and the thalassemias, which are caused by an alteration in normal hemoglobin molecules. The main structural hemoglobin variants are HbS, HbE and HbC. The main types of thalassemia are alpha-thalassemia and beta thalassemia. The two conditions may overlap because some conditions, which cause abnormalities in hemoglobin proteins also affect their production.

Some hemoglobin variants do not cause pathology or anemia, and thus are often not classed as hemoglobinopathies. Common symptoms of the condition include, severe pain, shortness of breath, enlarged spleen, and growth problems in children. It can be any group of disorders caused by the presence of variant hemoglobin in the red blood cells.

Market Dynamics

Increasing adoption of organic growth strategies, such as partnerships by key players in the market to expand their product portfolio, is expected to drive the market growth over the forecast period. For instance, in June 2022, Precision BioSciences, a publicly traded American clinical stage gene editing company, and Novartis AG, a pharmaceutical corporation, announced that they have entered into a partnership to develop new gene therapy for blood disorders.

Key features of the study:

• This report provides in-depth analysis of the global hemoglobinopathy market, and provides market size (US$ Million) and Compound Annual Growth Rate (CAGR%) for the forecast period (2023–2030), considering 2022 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global hemoglobinopathy market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study are Anamol Laboratories Pvt. Ltd., Bio-Rad Laboratories, Inc., PerkinElmer Inc., Zentech, Sebia, Sysmex Europe SE, Nanjing Poclight Biotechnology Co., Ltd, Abbott, Danaher, ReachBio LLC, Shenzhen Mindray Bio-Medical Electronics Co., Ltd., Nexcelom Bioscience LLC., NIHON KOHDEN CORPORATION, Siemens Healthcare GmbH, CRISPR Therapeutics.
• Insights from this report will allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global hemoglobinopathy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global hemoglobinopathy market

Detailed Segmentation:

• Global Hemoglobinopathy Market, By Test Type:

Routine Red Blood Cell (RBC) count

Genetic Testing

Hemoglobin by high performance liquid chromatography

Hemoglobin isoelectric focusing ( Hb IEF)

Hemoglobin electrophoresis (Hb ELP)

Hemoglobin solubility test

• Global Hemoglobinopathy Market, By Indication:

Sickle Cell Disease

Beta Thalassemia

Alpha Thalassemia

• Global Hemoglobinopathy Market, By End User:

Hospitals

Diagnostic Laboratories

Clinics

• Global Hemoglobinopathy Market, By Region:

North America

• By Country:

U.S.

Canada

Latin America

• By Country:

Brazil

Mexico

Argentina

Rest of Latin America

Europe

• By Country:

Germany

U.K.

France

Italy

Spain

Russia

Rest of Europe

Asia Pacific

• By Country

China

India

Japan

Australia

South Korea

ASEAN

Rest of Asia Pacific

Middle East

• By Country:

GCC

Israel

Rest of Middle East

Africa

• By Country/Region:

South Africa

Central Africa

North Africa

• Company Profiles

Anamol Laboratories Pvt. Ltd.*

• Company Highlights
• Products Portfolio
• Key Highlights
• Financial Performance
• Strategies

Bio-Rad Laboratories, Inc.

PerkinElmer Inc.

Zentech

Sebia

Sysmex Europe SE

Nanjing Poclight Biotechnology Co., Ltd

Abbott

Danaher

ReachBio LLC

Shenzhen Mindray Bio-Medical Electronics Co., Ltd.

Nexcelom Bioscience LLC.

NIHON KOHDEN CORPORATION

Siemens Healthcare GmbH.

CRISPR Therapeutics

“*” marked represents similar segmentation in other categories in the respective section.